Trial Profile
Effects of F17464 in Acute Exacerbation of Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2016
Price :
$35
*
At a glance
- Drugs F 17464 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms FAST
- Sponsors Pierre Fabre
- 26 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 09 Nov 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.